Loading...
•
Sep 30, 2021
Disc Medicine Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021 and provided a business update.
Key Takeaways
Gemini Therapeutics reported a net loss of $18.6 million, or $0.43 per share, for the three months ended September 30, 2021. The company held $150.1 million in cash as of September 30, 2021.
Presented safety data from ReGAtta Phase 2a study of GEM103 at AAO 2021, showing it was generally well-tolerated with no increased risk of CNV.
Presented GEM103 biology and development at the 2nd Annual Dry AMD Therapeutic Development Summit.
Announced corporate restructuring to prioritize late-stage clinical development of GEM103 for GA.
Presented preclinical data on GEM103 at the 13th International Conference on Complement Therapeutics.
Forward Guidance
The company is scheduled to meet with the FDA in Q4 2021 and expects to initiate a late-stage trial for GEM103 in patients with GA in Q1 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...